Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients

Objective: To evaluate the effect of oral contraceptive on the serum free prostatic specific antigen (PSA) in women with polycystic ovary syndrome (PCOD) compared with cyproterone compound. Materials and methods: In this randomized clinical trial, 60 hirsute PCOD patients that referred to Imam Hosse...

Full description

Bibliographic Details
Main Authors: R. Taheripanah, M. Sepahvandi, A. Entezari, Z. Amiri, E. Neisani Samani
Format: Article
Language:English
Published: SpringerOpen 2010-07-01
Series:Middle East Fertility Society Journal
Subjects:
PSA
Online Access:http://www.sciencedirect.com/science/article/pii/S1110569010000580
id doaj-e114d02d07294c46b3e28d992f2c65d6
record_format Article
spelling doaj-e114d02d07294c46b3e28d992f2c65d62020-11-25T02:32:27ZengSpringerOpenMiddle East Fertility Society Journal1110-56902010-07-0115315916210.1016/j.mefs.2010.06.007Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patientsR. Taheripanah0M. Sepahvandi1A. Entezari2Z. Amiri3E. Neisani Samani4Shahid Beheshti University of Medical Science (Mc.s), Infertility and Reproductive Health Research Center (IRHRC), Imam Hossein Hospital, Tehran, IranShahid Beheshti University (Mc.s), Imam Hossein Hospital, Tehran, IranShahid Beheshti University of Medical Sciences, Infertility & Reproductive Health Research Center (IRHRC), Tehran, IranShahid Beheshti University of Medical Science (Mc.s), Tehran, IranShahid Beheshti University (Mc.s), Imam Hossein Hospital, Tehran, IranObjective: To evaluate the effect of oral contraceptive on the serum free prostatic specific antigen (PSA) in women with polycystic ovary syndrome (PCOD) compared with cyproterone compound. Materials and methods: In this randomized clinical trial, 60 hirsute PCOD patients that referred to Imam Hossein hospital were enrolled. Baseline Ferriman–Gallway score (FG), body mass index (BMI), free PSA, 17-hydroxy progesterone (17-OHP), free testosterone, and dehydroepiandrestandione sulfate (DHEAS) were measured. Then patients were divided randomly into two groups. One group received oral contraceptive pill (OCP) and the other one ate cyproterone compound (Diane). Hormonal profile and Ferriman–Gallway scores were evaluated again after 3months. Results: Baseline FG score was 10.78±2.4 vs. 11.5±2.3 in OCP and cyproterone compound group, respectively. FG score was reduced after 3months to 8.06±2.5 vs. 9.2±2.3, respectively (P value=0.000). There was no significant difference in FG score reduction after the treatment between two groups (r>0.05). Baseline PSA was 0.201±0.3 in OCP group and 0.097±0.12ng/ml in cyproterone compound group and after the treatment was decreased in both groups significantly 0.135±0.24 vs. 0.059±0.05ng/ml, respectively, but the mean reduction of score was the same for both groups (r>0.5). Free testosterone reduced more in OCP group (2.48±1.3ng/ml to 2.24±1.0ng/ml, P value=0.03) than cyproterone compound (2.00±1.2 to 1.64±0.9ng/ml, P value=0.1). There was no statistical differences observed in 17-OHP and DHEAS after the treatment in both groups (P value >0.5). Conclusion: Serum free PSA and free testosterone and FG score were decreased after treatment with OCP and cyproterone compound but there was no preference between the two groups of anti-androgen treatment.http://www.sciencedirect.com/science/article/pii/S1110569010000580PSAHirsutismFerriman–Gallway scoreFree testosterone
collection DOAJ
language English
format Article
sources DOAJ
author R. Taheripanah
M. Sepahvandi
A. Entezari
Z. Amiri
E. Neisani Samani
spellingShingle R. Taheripanah
M. Sepahvandi
A. Entezari
Z. Amiri
E. Neisani Samani
Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients
Middle East Fertility Society Journal
PSA
Hirsutism
Ferriman–Gallway score
Free testosterone
author_facet R. Taheripanah
M. Sepahvandi
A. Entezari
Z. Amiri
E. Neisani Samani
author_sort R. Taheripanah
title Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients
title_short Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients
title_full Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients
title_fullStr Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients
title_full_unstemmed Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients
title_sort evaluation of serum psa after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients
publisher SpringerOpen
series Middle East Fertility Society Journal
issn 1110-5690
publishDate 2010-07-01
description Objective: To evaluate the effect of oral contraceptive on the serum free prostatic specific antigen (PSA) in women with polycystic ovary syndrome (PCOD) compared with cyproterone compound. Materials and methods: In this randomized clinical trial, 60 hirsute PCOD patients that referred to Imam Hossein hospital were enrolled. Baseline Ferriman–Gallway score (FG), body mass index (BMI), free PSA, 17-hydroxy progesterone (17-OHP), free testosterone, and dehydroepiandrestandione sulfate (DHEAS) were measured. Then patients were divided randomly into two groups. One group received oral contraceptive pill (OCP) and the other one ate cyproterone compound (Diane). Hormonal profile and Ferriman–Gallway scores were evaluated again after 3months. Results: Baseline FG score was 10.78±2.4 vs. 11.5±2.3 in OCP and cyproterone compound group, respectively. FG score was reduced after 3months to 8.06±2.5 vs. 9.2±2.3, respectively (P value=0.000). There was no significant difference in FG score reduction after the treatment between two groups (r>0.05). Baseline PSA was 0.201±0.3 in OCP group and 0.097±0.12ng/ml in cyproterone compound group and after the treatment was decreased in both groups significantly 0.135±0.24 vs. 0.059±0.05ng/ml, respectively, but the mean reduction of score was the same for both groups (r>0.5). Free testosterone reduced more in OCP group (2.48±1.3ng/ml to 2.24±1.0ng/ml, P value=0.03) than cyproterone compound (2.00±1.2 to 1.64±0.9ng/ml, P value=0.1). There was no statistical differences observed in 17-OHP and DHEAS after the treatment in both groups (P value >0.5). Conclusion: Serum free PSA and free testosterone and FG score were decreased after treatment with OCP and cyproterone compound but there was no preference between the two groups of anti-androgen treatment.
topic PSA
Hirsutism
Ferriman–Gallway score
Free testosterone
url http://www.sciencedirect.com/science/article/pii/S1110569010000580
work_keys_str_mv AT rtaheripanah evaluationofserumpsaaftercyproteronecompoundtreatmentcomparedwithoralcontraceptivepillinhirsutepolycysticovarysyndromepatients
AT msepahvandi evaluationofserumpsaaftercyproteronecompoundtreatmentcomparedwithoralcontraceptivepillinhirsutepolycysticovarysyndromepatients
AT aentezari evaluationofserumpsaaftercyproteronecompoundtreatmentcomparedwithoralcontraceptivepillinhirsutepolycysticovarysyndromepatients
AT zamiri evaluationofserumpsaaftercyproteronecompoundtreatmentcomparedwithoralcontraceptivepillinhirsutepolycysticovarysyndromepatients
AT eneisanisamani evaluationofserumpsaaftercyproteronecompoundtreatmentcomparedwithoralcontraceptivepillinhirsutepolycysticovarysyndromepatients
_version_ 1724819101326508032